RHB keeps buy on Tenaga, TA Securities keeps buy on Duopharma
RHB Research maintains a buy call on Tenaga Nasional with a RM16.50 target price, citing robust data centre demand and 856mw of new energy supply agreements in 1H26. TA Securities keeps a buy on Duopharma Biotech at RM1.69, expecting softer government sales in 2H26 offset by private and export demand.